Company Filing History:
Years Active: 2007-2010
Title: Charles Pellerin: Innovator in Hepatitis C Research
Introduction
Charles Pellerin is a notable inventor based in Laval, Canada. He has made significant contributions to the field of medical research, particularly in the development of innovative assay systems for hepatitis C virus (HCV) research. With a total of 2 patents, Pellerin's work is instrumental in advancing our understanding of viral protease activity.
Latest Patents
One of Pellerin's latest patents is a surrogate cell-based system and method for assaying the activity of hepatitis C virus NS3 protease. This invention focuses on creating a cell-based assay system that exhibits improved sensitivity to HCV NS3 protease activity compared to existing assays. The system is designed to screen test compounds that can modulate, particularly inhibit, HCV NS3 protease activity. It includes a first construct with a transactivator domain linked to the NS3-5 domains of HCV, controlled by a non-cytopathic viral promoter system. Additionally, a second construct features a reporter gene regulated by an operator sensitive to the transactivator's binding. This innovative approach allows for measurable transcription and expression of the reporter gene, enhancing the potential for effective screening of therapeutic compounds.
Career Highlights
Charles Pellerin is currently employed at Boehringer Ingelheim (Canada) Ltd., where he continues to contribute to groundbreaking research in the pharmaceutical industry. His work focuses on developing advanced methodologies for understanding and combating viral infections.
Collaborations
Pellerin collaborates with various professionals in his field, including his coworker Daniel Lamarre. Their combined expertise fosters an environment of innovation and progress in medical research.
Conclusion
Charles Pellerin's contributions to hepatitis C research through his innovative patents and collaborative efforts highlight his role as a key figure in the scientific community. His work continues to pave the way for advancements in the understanding and treatment of viral infections.